Interested in participating in a meta-analysis of informant-reported SCD criteria and their links to AD biomarkers? Your cohort assesses informant-reports and Aβ or tau in CU elderly or SCD patients? Join our @SCDPIA working group (A&T and Dyadic pattern cross-projects) [1/3]

🧠 If you’ve been following or contributing to research on #SCD (or any related PIA), take a few minutes to share: 👉 key advances, impactful papers (self-citations count 😉), hot topics Deadline: Dec 5 🗓️ https://t.co/lCm0xxc8mV @SCDPIA @ISTAART #alzheimer #yearinreview

Have you read an outstanding study on subjective cognitive decline (SCD) published in 2025? Nominate it for the 2025 ISTAART SCD PIA Publication of the Year Award! https://t.co/Kk4tLReJTx ✅ Self-nominations are welcome 🗓️ Open until February 2026 #SCD #Alzheimer

The officers of the @INSneuro Dementia SIG are seeking volunteers to participate in a workgroup on transitional cognitive decline in Alzheimer's disease. If you're interested in taking part, fill out this survey by 1/10: https://t.co/7g0OJvVNNR

Félicitations à @RobindeFlores, lauréat du Prix Joël Ménard 2024 en recherche clinique et translationnelle 🧠! 📷 Découvrez son travail qui révolutionne la compréhension d'Alzheimer : https://t.co/4MRtvH0ywu #Recherche #Alzheimer #PrixJoelMenard

📚 Have you come across studies published between January 1st and December 31st, 2024, that you found particularly relevant? Help us prepare the SCD PIA Year in Review (coming January 2025) by sharing them with us! 🌟 Self-nominations are welcome! 👉

🚨 Starting in 30 minutes! 🚨 Join us for the 30-min Subjective Cognitive Decline Journal Club with @MarkDubbleman, presenting a paper by @NickGrunden

Looking forward to tomorrow's Journal Club discussion! 📚✨ Still time to register if you haven’t yet—don’t miss out on a great conversation!

IWG 2024 vs AA 2024 criteria for Alzheimer disease A comparison between the recently proposed Alzheimer Association criteria vs the updated IWG criteria for AD. Differences are in the Table below: mainly comprising differing views on AD as a "biological" vs "clinical-biological"

🌟 Excited to introduce our Executive Committee for 2024-2026! We’re thrilled to present the amazing team working in the SCD field. Check out the slides below to meet each member! ⬇️ @SCDPIA @ISTAART

📢 POSTDOC position at @biofinder_study @BarcelonaBeta still open! 👩🏽‍💻🧑🏿‍💻👩🏻‍💻🧠📊 📩 Contact us for more info! https://t.co/OevoY4tu2H https://t.co/ynMhp2BzuT

🚨 Join us for the @SCDPIA @ISTAART "Journal Club: Meet the Author" on Nov 6 at 10:00 AM CT! 🧠 🔗 Read the article: https://t.co/wQ90mNPZRA 🔗 Register now: https://t.co/w403eO4SdF Featuring @markdbm, @ElizabethKuhn7, & author @NickGrunden

⌛️The 1st edition of #EUMIND is in 1 week Very much looking forward to these 3 days of science 🧠, networking 🤝 and social activities 🎞️🍎 See you in 1 week in #Caen 🇫🇷 📍All info at https://t.co/UVfrpoW5Hd @eumind_congress

Really excited to host this upcoming webinar on Friday October 11 where @markdbm will present his work on measuring clinically meaningful change in daily functioning in ADRD. Link to register is below: https://t.co/yiVL6xdU9m @DesignDataPIA #Statistics #NeuroTwitter

📢 Exciting News! We currently have 6 active working groups, with some still accepting new members! Got a new idea for a working group? We'd love to hear it! 💡 Feel free to reach out via email or private message here to get involved or share your ideas! 💬 #SCDPIA @ISTAART

📢 Join us TODAY for the Subjective Cognitive Decline PIA All Members Meeting at 9 AM CDT! 🧠 Don't miss out — there's still time to register: https://t.co/IKUfRlz2SP ⏰ Not sure about your local time? Find it here:

It also suggests that Stage 2 AD risk group could be defined in studies relying solely on plasma biomarkers if combined with an established SCD measure. This may facilitate future studies in regions and for individuals without access to invasive or expensive amyloid measurements

This demonstrates that SCD combined with amyloid positivity is a robust and tangible indicator of clinical Stage 2 of the biological AD continuum.

This was found using different operationalisations of SCD and amyloid (categorical vs dimensional, PET vs plasma Ab42/40). Similar findings were found in the SILCODE even in the absence of a memory clinic consultation (SCD-community)

SCD+Ab+ participants showed steeper cognitive decline or fewer training effects than the other 3 groups in DELCODE and SILCODE combined and stratified.

Super proud and happy to share my first paper published as last author, co-supervising @Kai_Shao_ on the CLoCODE project, a Sino-German collaboration! Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts -